Projects could include the production of flu vaccines.

Neugenesis and Universidad de los Andes have expressed interest in forming a joint venture R&D project. The organizations signed a memorandum of understanding for possible R&D projects like the manufacturing of a seasonal influenza vaccine utilizing Neugenesis’ production system.

Neugenesis will provide its fungal protein expression platforms for high level protein manufacturing. The Universidad de los Andes will offer expertise through its professors and graduate assistances.

Neugenesis reports that the NeuBIOS™ and the NeuKARYON™ platforms allow for rapid generation of production strains expressing a wide range of therapeutic proteins. These platforms are readily scalable, and manufacturing requires significantly less infrastructure than traditional methods, the firm adds.

Previous articleArQule to Pocket $75M Upfront through Deals with Daiichi-Sankyo
Next articleCelldex Enters Licensing Deal to Develop CD27 mAbs for Cancer